Embryonal Tumor with Multilayered Rosettes Overview
Learn About Embryonal Tumor with Multilayered Rosettes
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Thomas Spencer is a Radiation Oncologist in Florence, South Carolina. Dr. Spencer and is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Familial Prostate Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Prostate Cancer. Dr. Spencer is currently accepting new patients.
Mcleod Regional Medical Center Of The Pee Dee, Inc
Sreenivas Rao is an Oncologist and a Hematologist in Florence, South Carolina. Dr. Rao and is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Acute Promyelocytic Leukemia, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Endoscopy. Dr. Rao is currently accepting new patients.
Mcleod Regional Medical Center Of The Pee Dee, Inc
Michael Pavy is a Hematologist Oncology specialist and a Hematologist in Florence, South Carolina. Dr. Pavy and is rated as an Experienced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Pavy is currently accepting new patients.
Summary: This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Aims: 1. To evaluate the safety and efficacy of GD2/B7H3 CAR-T therapy for relapsed/refractory neuroblastoma, and observe its pharmacokinetic/pharmacodynamic characteristics and the survival of CAR-T cells in relapsed/refractory neuroblastoma patients. 2. To evaluate the safety and efficacy of GD2/B7H3 CAR-T therapy for relapsed/refractory desmoplastic small round cell tumor, and observe its pharmacokin...